Skip to main content

Table 2 Fitted ADC and IVIM parameter estimates following vasomodulator challenge

From: Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform

   Kidney   Cortex   Medulla  
  Challenge pre post pre post pre post
  Hydralazine 10.9 ± 0.7 15.1 ± 0.8a 17.4 ± 2.1 24.4 ± 2.6a 7.2 ± 0.8 8.3 ± 1.3
f Furosemide 12.0 ± 1.4 10.1 ± 1.0 b 17.1 ± 1.0 12.0 ± 1.5a 9.6 ± 1.7 8.2 ± 1.3 b
(%) Angiotensin II 19.3 ± 1.5 18.7 ± 1.6 23.9 ± 2.9 21.6 ± 2.1 15.3 ± 1.5 13.3 ± 1.3
  Hydralazine 133.9 ± 5.9 100.2 ± 6.6a 130.3 ± 7.2 96.8 ± 8.8a 139.3 ± 4.0 109.6 ± 5.4a
D Furosemide 118.8 ± 5.8 138.8 ± 5.0a 117.5 ± 7.7 137.4 ± 7.9a 123.5 ± 5.4 141.6 ± 4.3a
(10−5 mm2s−1) Angiotensin II 118.8 ± 7.0 115.0 ± 4.4 116.4 ± 7.3 110.7 ± 4.7 129.1 ± 8.7 123.8 ± 5.7
  Hydralazine 130 ± 6.0 97.9 ± 7.1a 126.6 ± 6.5 87.9 ± 8.9a 139.0 ± 4.0 111.8 ± 6.2a
ADC Furosemide 117.1 ± 5.8a 136.2 ± 5.7a 114.1 ± 9.1a 134.5 ± 8.6a 122.7 ± 5.5a 141.1 ± 5.6a
(10−5 mm2s−1) Angiotensin II 110.9 ± 7.7 110.9 ± 3.9 103.1 ± 8.1 102.2 ± 4.7 126.0 ± 8.8 122.2 ± 2.7
  Termination 91.3 ± 9.5 68.0 ± 4.3a 84.1 ± 9.8 60.5 ± 5.3a 100.7 ± 10.2 79.0 ± 10.7
  Hydralazine 4.0 ± 0.2 5.0 ± 0.2a 3.3 ± 0.4 5.0 ± 0.2a 4.3 ± 0.3 4.9 ± 0.2a
D* Furosemide 3.6 ± 0.2 3.8 ± 0.1 3.2 ± 0.3 3.7 ± 0.2 3.8 ± 0.2 3.6 ± 0.2
(10−2 mm2s−1) Angiotensin II 4.3 ± 0.5 5.1 ± 0.3 4.2 ± 0.4 4.5 ± 0.3 4.3 ± 0.6 5.2 ± 0.4 b
  Hydralazine 38.7 ± 1.7 65.6 ± 1.9a 48.1 ± 3.4 96.7 ± 9.2a 25.2 ± 0.9 35.6 ± 3.7a
fD* Furosemide 38.4 ± 5.0 32.5 ± 3.2 48.4 ± 5.0 37.8 ± 4.3a 29.9 ± 4.7 25.0 ± 2.7
(10−4 mm2s−1) Angiotensin II 71.2 ± 11.5 80.8 ± 10.8 76.8 ± 9.4 83.0 ± 12.9 59.0 ± 12.3 62.8 ± 9.5
  1. Data are reported as mean of median ROI values ± standard error
  2. aindicates p < 0.05 against baseline
  3. bindicates p < 0.1 against baseline